A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
2017-05-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the efficacy and safety of an experimental drug,
demcizumab, when given in combination with pembrolizumab. Demcizumab is a humanized
monoclonal antibody and was developed to target cancer stem cells. Demcizumab may block the
growth of cancer stem cells, the remaining cancer cells, and it may also impair the
productive growth of new blood vessels, which tumors need to grow and spread.
This study is sponsored by OncoMed Pharmaceuticals, which is referred to as OncoMed or the
Sponsor in this consent form.